A novel cancer vaccine strategy based on HLA-A*0201 matched allogeneic plasmacytoid dendritic cells.

Caroline Aspord, Julie Charles, Marie-Thérèse Leccia, David Laurin, Marie-Jeanne Richard, Laurence Chaperot, Joël Plumas

Figure S1

A



B

		tumor antigen mRNA expression			
		MelA	GP100	TYR	MAGE-3
cell line	Me275	+	+	+	+
	Mel89	+	+	+	+
	COLO829	+	+	+	+
	A375	-	-	+low	-

Figure S2

A



B



C



D



Figure S3


A
Flu specific T cells
restimulation :
T2 Flu
T2 MelA
IFNγ
CD107
31%
1.3%
75.5%
11.9%
Flu tetramer
B
Flu specific T cells
% killing
100
80
60
40
20
0
60:1
30:1
15:1
7.5:1
E:T ratio
T2 Flu
T2 MelA
K562
C
PBMC + GEN Flu - d8
% of IFNγ+ T cells
60
40
20
0
restimulation :
MelA
Flu
MelA
Flu
-
T2
GEN
tetramer+ CD8 T cells
tetramer- CD8 T cells
CD4 T cells
D
PBMC + GEN Flu - d8
CD107+ T cells
80
60
40
20
0
restimulation :
MelA
Flu
MelA
Flu
-
T2
GEN
tetramer+ CD8 T cells
tetramer- CD8 T cells
CD4 T cells

Figure S4


A
response to MelA vaccination
lavage
blood
spleen
MLN
% tetramer CD8 T cells
10
1
0.1
0.01
0.001
d0
d10
d14
d21
d32
B
response to Flu vaccination
lavage
blood
spleen
MLN
% tetramer CD8 T cells
10
1
0.1
0.01
d0
d7
d14
d21
d32

Figure S5



Figure S6


CD80
CD86
HLA-A2
CD40
Counts
0
80
160
240
320
400
10^0
10^1
10^2
10^3
10^4
CD80 FITC
CD86 PE
HLA-A2 FITC
CD40 PE
untreated
30Gy irradiation

Figure S7



Figure S8


% of maximum lysis
(E:T ratio 30:1)
100
80
60
40
20
0
pDC line
mDC
1
0.1
0.01
0.001
0.0001
peptide concentration on T2 cells (µM)
T2 loaded
with irrelevant
peptide
unloaded
T2